Magnus Financial Group LLC Acquires New Holdings in BioAtla, Inc. (NASDAQ:BCAB)

Magnus Financial Group LLC bought a new stake in BioAtla, Inc. (NASDAQ:BCAB) during the 4th quarter, Holdings Channel.com reports. The fund bought 47,232 shares of the company’s stock, valued at approximately $28,000.

A number of other large investors have also added to or reduced their stakes in BCAB. XTX Topco Ltd grew its position in shares of BioAtla by 7.2% in the 3rd quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock worth $273,000 after buying an additional 10,384 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in BioAtla by 5.2% in the third quarter. Massachusetts Financial Services Co. MA now owns 569,332 shares of the company’s stock worth $1,002,000 after purchasing an additional 28,133 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of BioAtla during the third quarter worth $623,000. Chicago Partners Investment Group LLC acquired a new position in shares of BioAtla during the third quarter worth $44,000. Finally, Vontobel Holding Ltd. purchased a new stake in shares of BioAtla during the 3rd quarter valued at $28,000. 77.23% of the stock is currently owned by institutional investors.

BioAtla Stock Down 0.8 %

BCAB stock opened at $0.49 on Friday. The stock has a market capitalization of $23.91 million, a PE ratio of -0.29 and a beta of 1.17. BioAtla, Inc. has a 52 week low of $0.45 and a 52 week high of $4.02. The firm has a 50 day moving average of $1.04 and a 200 day moving average of $1.55.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.12. The company had revenue of $11.00 million for the quarter. During the same period in the prior year, the firm earned ($0.70) EPS. On average, equities research analysts expect that BioAtla, Inc. will post -1.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright downgraded BioAtla from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 13th.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.